Dr. Kelly Bolton, M.D.
Claim this profileWashington University School of Medicine
Studies Low blood cell count
Studies Anemia
5 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Kelly Bolton, M.D. is currently running
Biomarker-Driven Therapy
for Breast Cancer
This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with HR positive, HER-2 negative metastatic or unresectable breast cancer. Patients will receive first-line treatment with a CDK4/6 inhibitor (CDK4/6i) and endocrine therapy. All patients will have blood drawn for thymidine kinase activity (TKa) testing at baseline and at C1D15. Patients who are found to have a lack of TKa suppression at C1D15 will be recommended to switch to an alternative therapy. Patients with suppressed C1D15 TKa levels will continue on CDK4/6i and endocrine therapy until clinical progression. Patients with TKa which remains suppressed will be recommended to delay restaging scans from 24 weeks to 36 weeks. The investigators hypothesize that a patient's TKa level at C1D15 is prognostic for progression-free survival (PFS) on a CDK4/6 inhibitor and early therapeutic switching in patients with a lack of C1D15 TKa suppression will be associated with prolonged PFS.
Recruiting1 award N/A9 criteria
Enasidenib
for Clonal Cytopenia
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
Recruiting1 award Phase 2
More about Kelly Bolton, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Kelly Bolton, M.D. has experience with
- Enasidenib
- Ivosidenib
- Ruxolitinib
- CDK4/6 + Endocrine Therapy
- DiviTum® TKa Assay
Breakdown of trials Kelly Bolton, M.D. has run
Low blood cell count
Leukopenia
Thrombocytopenia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kelly Bolton, M.D. specialize in?
Kelly Bolton, M.D. focuses on Low blood cell count and Anemia. In particular, much of their work with Low blood cell count has involved IDH positive patients, or patients who are undergoing treatment.
Is Kelly Bolton, M.D. currently recruiting for clinical trials?
Yes, Kelly Bolton, M.D. is currently recruiting for 4 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Kelly Bolton, M.D. has studied deeply?
Yes, Kelly Bolton, M.D. has studied treatments such as Enasidenib, Ivosidenib, Ruxolitinib.
What is the best way to schedule an appointment with Kelly Bolton, M.D.?
Apply for one of the trials that Kelly Bolton, M.D. is conducting.
What is the office address of Kelly Bolton, M.D.?
The office of Kelly Bolton, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.